Meta Description:
Discover 3 Indian companies — Transformers & Rectifiers India, Blue Jet Healthcare, and Ashapura Minechem — that have delivered major earnings surprises in Q1 FY26 and could continue their growth momentum.
Earnings Surprise Stocks: 3 Companies Beating Market Expectations in FY26
Earnings Surprises: The Real Game-Changer in the Stock Market
In the stock market, one factor often changes the game completely — earnings surprises. When companies report results far better than expected and project continued growth, their stock prices often react dramatically.
History shows that true multibagger stories are born from consistent earnings surprises.
Take examples like FS Motors, PG Electroplast, and Shakti Pumps — all of them delivered strong results that exceeded market expectations and sustained their performance for several quarters. As a result, investors who spotted these surprises early were rewarded with magnificent returns.
Now, a new set of companies is showing similar signs. Let’s analyze three companies that have delivered strong earnings surprises recently and explore whether their growth momentum can continue.
1️⃣ Transformers & Rectifiers India (TRI): Powering Growth with Strong Orders
Earnings Surprise:
In Q1 FY26, Transformers & Rectifiers India (TRI) delivered a stellar performance:
- Revenue growth: +64% YoY to ₹529 crore
- Operating profit margin (OPM): Up 400 bps to 17%
- Net profit: Up 219% YoY to ₹67 crore
This massive jump was driven by a combination of volume growth, margin expansion, and strong demand visibility.
Business Overview:
TRI manufactures large transformers that power factories, railways, and power grids. It offers a wide product range — power, distribution, furnace, rectifier, and special transformers — with three manufacturing plants in Ahmedabad and exports to 25+ countries.
The company’s order book stands at a robust ₹5,246 crore, which is 260% of FY25 revenue, giving visibility for the next 15–18 months.
Operational Improvements:
- Backward integration and automation helped improve margins.
- Reduced dependence on raw material suppliers by acquiring controlling stakes.
- Cash from operations jumped 441% to ₹157 crore, with 44% of profits converted into cash.
Expansion Plans:
TRI plans to add 22,000 MVA to its existing 40,000 MVA capacity through a ₹550 crore capex plan over the next 15 months.
While borrowings increased 52% to ₹81 crore, the higher fixed assets (up 74%) reflect long-term growth investments.
Risks:
The main risk lies in supply chain dependency and extended credit cycles (6+ months). Since transformers require specialized parts, any delay in supply could affect production.
Verdict: TRI’s order book and profit momentum look promising, but working capital management needs close monitoring.
2️⃣ Blue Jet Healthcare: Pharma Intermediates on a Growth Spree
Earnings Surprise:
In Q1 FY26, Blue Jet Healthcare reported:
- Revenue: ₹355 crore (+118% YoY)
- Operating Profit: ₹121 crore (+175% YoY)
- OPM: Up 700 bps to 34%
- Profit: 2.4x increase YoY
Business Overview:
Blue Jet is a B2B pharma company specializing in APIs, pharma intermediates, contrast media chemicals (for MRI & CT scans), and sweeteners. It follows a CDMO model (Contract Development and Manufacturing Organization) and is India’s largest exporter of contrast media intermediates.
Exports form the bulk of its revenue — 42% from France, 34% from Norway, and 11% from the US. With the US imposing new tariffs on pharma imports, the limited exposure (11%) minimizes risk.
Financial Highlights:
Revenue doubled due to higher volumes in APIs and intermediates.
However, cash flow from operations declined 80% to ₹46 crore, showing weak cash realization due to rising receivables and inventory.
The cash conversion cycle increased from 26 days to 262 days, signaling that rising debt and inventory days are stretching liquidity. The company might need to depend more on short-term borrowing.
Growth Outlook:
Management has guided for sustained volume growth in APIs, intermediates, and sweeteners in H2 FY26. But investors should track cash flow health closely.
Risks:
- High revenue concentration in Europe makes it vulnerable to regulatory or demand risks.
- Rising receivables could weaken cash flow despite robust sales growth.
Verdict: Blue Jet’s earnings surprise is impressive, but cash conversion issues may limit short-term upside. A turnaround in working capital efficiency could reignite strong stock performance.
3️⃣ Ashapura Minechem: Mining Growth from Global Expansion
Earnings Surprise:
In Q1 FY26, Ashapura Minechem surprised the market with:
- Revenue: ₹10,356 crore (+90% YoY)
- Operating Profit: ₹182 crore (+119% YoY)
- OPM: Up 100 bps to 13%
- Profit: 2x increase YoY
Business Overview:
Ashapura Minechem is a multi-mineral company producing bentonite, bauxite, zeolites, and bleaching clay. Its products serve multiple sectors — steel, ceramics, edible oil, and pharmaceuticals.
It holds a 15% share in India’s bauxite exports, is the third-largest bentonite producer globally, and exports to 80+ countries. Exports account for 82% of revenue, highlighting its global reach.
Growth Outlook:
The company is aggressively expanding its Guinea operations, where it mines bauxite and iron ore. Guinea’s reserves make it a global hub for bauxite, and Ashapura has been active there since 2016.
Fixed assets jumped 1133% in FY25, mainly due to capacity expansion in Guinea and India.
Cash from operations increased 27% to ₹118 crore, with nearly 49% of profits converted into cash, showing efficiency improvement.
Risks:
- Concentration risk: 70% of revenue comes from Guinea. Any political or climatic issues (monsoon season disruption) could affect mining and logistics.
- Cash conversion cycle: Increased sharply from 12 to 103 days, suggesting delayed cash realization.
- Receivables doubled, indicating extended customer credit terms.
Verdict: Ashapura’s global expansion and strong demand look promising, but cash cycle elongation and geographic concentration remain key watchpoints.
📊 Key Takeaways:
| Company | Q1 FY26 Revenue Growth | Profit Growth | OPM Change | Key Concern |
|---|---|---|---|---|
| Transformers & Rectifiers India | +64% | +219% | +400 bps | Working capital cycle |
| Blue Jet Healthcare | +118% | +140% | +700 bps | Weak cash realization |
| Ashapura Minechem | +90% | +119% | +100 bps | High receivables, cash cycle |
📈 Conclusion: Watch These Earnings Surprise Stocks Closely
Earnings surprises are where multi-bagger journeys begin.
Companies like Transformers & Rectifiers India, Blue Jet Healthcare, and Ashapura Minechem have delivered exceptional results and strong profit growth.
However, the next big question is:
👉 Can they sustain earnings momentum over the next 6–8 quarters?
If they do, these names might turn out to be the next hidden multibaggers — but investors must monitor working capital, cash flow, and geographic risks closely.
Disclaimer: This article is for educational purposes only and should not be considered financial advice.As always, do your own due diligence and consult a financial advisor before investing.
Investment in securities markets is subject to market risks. Please read all related documents carefully before investing.
ALSO READ
Follow me on Twitter (X) or Facebook Group for Updates.
Liked our article ? Subscribe to get weekly updates